



## **Axcella to Report First Quarter 2021 Financial Results on May 6, 2021**

April 27, 2021

*Conference call to take place at 8:30 a.m. ET*

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2021-- [Axcella](#) (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

The conference call webcast will be available in the Investors & News section on the company's website at [www.axcellahealth.com](http://www.axcellahealth.com). To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company's website for 90 days following the call.

### **Internet Posting of Information**

Axcella uses its website, [www.axcellahealth.com](http://www.axcellahealth.com), as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company's website in the "Investors and News" section. Accordingly, investors should monitor this portion of the company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

### **About Axcella**

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit [www.axcellahealth.com](http://www.axcellahealth.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20210427005275/en/>

Jason Fredette  
[jfredette@axcellahealth.com](mailto:jfredette@axcellahealth.com)  
857.320.2236

Source: Axcella